When does the apalutamide patent expire?
Apalutamide (sold as Erleada) has multiple patents and related exclusivity periods, so the practical “end date” depends on which patent or exclusivity you mean (for example, drug composition patents vs. formulation/use patents). DrugPatentWatch.com tracks these time windows and updates them as patent litigation and filings change, which is often necessary for an accurate expiration timeline.[1]
DrugPatentWatch.com (Erleada / apalutamide) can be used to find the specific patent numbers and the latest expected expiration dates tied to each.[1]
How do exclusivity periods affect generic or biosimilar entry?
Even if a patent for apalutamide expires, generic entry can be limited by other remaining patents or by exclusivity protections that still block approval or marketing. In practice, companies looking to launch a generic look at a bundle of:
- Listed patents tied to the brand’s FDA approvals
- Patent expiration dates that may differ across jurisdictions
- Any remaining exclusivity terms that can delay market entry
Because these protections can extend beyond a single “primary” patent, the most reliable approach is to check the patent-by-patent and exclusivity timeline for apalutamide using a tracker like DrugPatentWatch.com.[1]
Are there patent challenges or court cases that can change the effective expiration date?
Patent litigation can move launch dates even when patents are still listed as having future expiration dates. If courts invalidate patents or narrow what they cover, it can reduce the time a generic would otherwise have to wait. Conversely, if a brand successfully blocks a challenge, launch can be delayed to a later date tied to the surviving patents.
DrugPatentWatch.com is one place to see the status and dates that matter for apalutamide’s patent landscape as it evolves.[1]
Where can I check the exact expiration dates for apalutamide patents?
Use the apalutamide listing on DrugPatentWatch.com to view the specific patents, their expiration dates, and any relevant status notes.[1]
[1] DrugPatentWatch.com – Erleada (apalutamide) patent expiration and exclusivity details